Caribou Biosciences NASDAQ:CRBU reported a series of insider transactions involving Chief Technology Officer Timothy P. Kelly in filings with the Securities and Exchange Commission.
According to a Form 4 filed with the SEC, Kelly sold 3,147 shares of Caribou common stock on February 24, 2026. The transaction price was $1.96 per share, producing total proceeds of $6,168.
The same filing shows prior activity on February 20, 2026, when Kelly acquired 45,000 shares of common stock that were recorded with a value of $0. In addition, Kelly received options on that date granting the right to purchase 202,500 shares of common stock at an exercise price of $1.80 per share. Those options carry an expiration date of February 19, 2036.
Following the sale executed on February 24, 2026, Kelly is recorded as directly owning 79,353 shares of Caribou Biosciences common stock.
In separate analyst activity noted in the filings, Clear Street has initiated coverage on Caribou Biosciences with a Buy rating and a price target of $13.00. The research note expressed optimism about the company’s development of off-the-shelf allogeneic CAR-T cell therapies, stating these therapies are seen as having the potential to compete commercially in the market.
The filings provide a concise record of the insider transactions and the new analyst coverage. The sale on February 24, 2026 and the acquisitions recorded on February 20, 2026 appear together in the SEC filing, which also documents the option grant and its ten-year term. The Clear Street initiation and price target are reported alongside the transaction details in the public filing record.
Summary - Timothy P. Kelly, CTO of Caribou Biosciences, sold 3,147 shares on February 24, 2026 for $6,168, acquired 45,000 shares on February 20, 2026 with a recorded value of $0, and received options to buy 202,500 shares at $1.80 that expire in 2036. After the sale, Kelly directly owns 79,353 shares. Clear Street initiated coverage with a Buy rating and a $13.00 price target, citing potential in allogeneic CAR-T therapies.
Contextual note - The SEC Form 4 is the source for the transaction details and ownership figures reported here; the analyst rating and price target are taken from the initiation report noted in connection with the filings.